{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Genotyping&page=30",
    "query": {
      "intervention": "Genotyping",
      "page": 30
    },
    "page_size": 10
  },
  "pagination": {
    "page": 30,
    "page_size": 10,
    "total_count": 732,
    "total_pages": 74,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Genotyping&page=31&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Genotyping&page=29&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T10:43:02.024Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01581138",
      "title": "VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C Virus"
      ],
      "interventions": [
        {
          "name": "VX-222",
          "type": "DRUG"
        },
        {
          "name": "telaprevir",
          "type": "DRUG"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 64,
      "start_date": "2012-07",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-07-04",
      "last_synced_at": "2026-10-22T10:43:02.024Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Anaheim, California • Riverside, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01581138"
    },
    {
      "nct_id": "NCT04454190",
      "title": "Development and Validation of a Model to Predict Fast Progression in Glaucoma",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glaucoma",
        "Primary Open Angle Glaucoma",
        "Glaucoma, Suspect"
      ],
      "interventions": [
        {
          "name": "Collection of genetic material",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 1152,
      "start_date": "2021-07-20",
      "completion_date": "2023-04-24",
      "has_results": false,
      "last_update_posted_date": "2024-03-25",
      "last_synced_at": "2026-10-22T10:43:02.024Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04454190"
    },
    {
      "nct_id": "NCT04502017",
      "title": "Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Device-Related Thrombosis",
        "Atrial Fibrillation",
        "Left Atrial Appendage Occlusion"
      ],
      "interventions": [
        {
          "name": "ASA plus Clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "Genetic-Tailored AntiThrombotic Strategy",
          "type": "DRUG"
        },
        {
          "name": "Half-Dose of novel OAC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Texas Cardiac Arrhythmia Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 360,
      "start_date": "2020-08-05",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-08-07",
      "last_synced_at": "2026-10-22T10:43:02.024Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04502017"
    },
    {
      "nct_id": "NCT04601155",
      "title": "Transition of Renal Patients Using AlloSure Into Community Kidney Care",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Kidney Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "AlloSure",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "CareDx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 248,
      "start_date": "2020-11-19",
      "completion_date": "2023-10-06",
      "has_results": false,
      "last_update_posted_date": "2023-11-03",
      "last_synced_at": "2026-10-22T10:43:02.024Z",
      "location_count": 18,
      "location_summary": "Fairfield, California • Fresno, California • Granada Hills, California + 15 more",
      "locations": [
        {
          "city": "Fairfield",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04601155"
    },
    {
      "nct_id": "NCT01485991",
      "title": "TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "TMC435",
          "type": "DRUG"
        },
        {
          "name": "TVR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen R&D Ireland",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 771,
      "start_date": "2012-02",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2016-04-26",
      "last_synced_at": "2026-10-22T10:43:02.024Z",
      "location_count": 32,
      "location_summary": "Bakersfield, California • San Diego, California • Aurora, Colorado + 29 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01485991"
    },
    {
      "nct_id": "NCT01694875",
      "title": "Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Human Papillomavirus Infection"
      ],
      "interventions": [
        {
          "name": "APTIMA HPV Assay",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Gen-Probe, Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "21 Years and older · Female only"
      },
      "enrollment_count": 2200,
      "start_date": "2012-10",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2012-11-14",
      "last_synced_at": "2026-10-22T10:43:02.024Z",
      "location_count": 3,
      "location_summary": "Minneapolis, Minnesota • Burlington, North Carolina • Maryville, Tennessee",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Burlington",
          "state": "North Carolina"
        },
        {
          "city": "Maryville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01694875"
    },
    {
      "nct_id": "NCT00001667",
      "title": "Genotype/Phenotype Correlation of Movement Disorders and Other Neurological Diseases",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Movement Disorders",
        "Myoclonus",
        "Nervous System Diseases",
        "Tic Disorders",
        "Tremor"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 300,
      "start_date": "1997-03",
      "completion_date": "2000-04",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-22T10:43:02.024Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001667"
    },
    {
      "nct_id": "NCT02073656",
      "title": "Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C Virus",
        "HIV"
      ],
      "interventions": [
        {
          "name": "LDV/SOF",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 335,
      "start_date": "2014-02",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2018-11-16",
      "last_synced_at": "2026-10-22T10:43:02.024Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02073656"
    },
    {
      "nct_id": "NCT00578344",
      "title": "Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Hemoglobin SC"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Campath 1H",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide and MESNA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Tami D. John",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "Up to 40 Years"
      },
      "enrollment_count": 8,
      "start_date": "2005-07",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2020-07-31",
      "last_synced_at": "2026-10-22T10:43:02.024Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00578344"
    },
    {
      "nct_id": "NCT01434498",
      "title": "GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Genotype 1a or 1b HCV Infection"
      ],
      "interventions": [
        {
          "name": "GS-5885 tablet",
          "type": "DRUG"
        },
        {
          "name": "GS-9451 tablet",
          "type": "DRUG"
        },
        {
          "name": "tegobuvir capsule",
          "type": "DRUG"
        },
        {
          "name": "ribavirin tablet",
          "type": "DRUG"
        },
        {
          "name": "placebo matching ribavirin tablet",
          "type": "DRUG"
        },
        {
          "name": "placebo matching tegobuvir capsule",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 163,
      "start_date": "2011-09",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2013-12-20",
      "last_synced_at": "2026-10-22T10:43:02.024Z",
      "location_count": 36,
      "location_summary": "Beverly Hills, California • Coronado, California • La Jolla, California + 28 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01434498"
    }
  ]
}